Histonyx Models
AI tissue scoring for IBD — built to read histologic activity and healing consistently across thousands of slides, for trials and research.
Quantum histology · GI pathology · Decentralized trials
Every patient.
Every stain.
Every slide.
Histonyx turns ~3 million biopsy-confirmed GI cases — repeat biopsies from the same patients, special stains beyond H&E, linked medications, and slide images — into cohorts, AI-ready data, and decentralized trials.
~3MGI pathology cases
~15,000digitized slide images
~10 yrscontinuous case history
4+stain families per tissue: H&E, special stains, IHC
Approximate ranges. Final counts are confirmed in a feasibility review.
01 — The record
One patient. Every layer.
Claims data tells you a code was billed. Histonyx shows what the tissue looked like, what the patient was taking, and how the disease changed between biopsies.
Pathologist-confirmed diagnosis — not a billing code.
HX-0042817
Illustrative synthetic record
Diagnosis
Ulcerative colitis, chronic active
- 2017Active colitis, crypt abscesses
- 2019Persistent activity
- 2021Quiescent — histologic remission
- 2024Mild relapse
H&EPASTrichromeCMV IHC — negKi-67 IHC
2017–195-ASA
2019–24Biologic
2024–Small molecule
02 — Beyond H&E
The same tissue, four ways.
Most pathology datasets stop at the routine stain. Histonyx cases carry special stains and immunohistochemistry, so you can define cohorts by what the tissue expressed, not just what it was called.
03 — The gap
What claims and EHR data can't see.
- Typical real-world data
- Histonyx
- Diagnosis codes
- Pathologist-confirmed diagnosis
- One snapshot in time
- Repeat biopsies from the same patient
- No tissue detail
- Special stains and IHC
- Prescriptions in a separate dataset
- Medications linked to the patient
- No images
- Digitized whole-slide images
- Patients out of reach
- A consented path to enroll
04 — From count to trial
We don't just tell you the patients exist. We help you reach them.
- 01
Find
Count patients who match your protocol — by diagnosis, stain result, treatment history, state, and year.
- 02
Characterize
Review the cohort's tissue findings, stain panels, slide images, and treatment patterns before you commit.
- 03
Enroll
Reach patients through their own physicians, with consent, and onboard them into a decentralized study.
- 04
Follow
Capture symptoms and outcomes remotely at home, with fewer site visits.
A decade of GI disease, read cell by cell.
05 — Who it's for
Built for the teams that move molecules.
RWD and data partnerships
License linked tissue, stain, and medication data that claims can't provide.
RWE, epidemiology, HEOR
Measure tissue-level disease and treatment response over time in biopsy-confirmed cohorts.
Clinical development
Size protocols before launch, then recruit the patients through Histonyx.
Translational and AI
Train and validate biomarkers and models on slides linked to stain results and treatment.
Medical affairs
Show what happens in the tissue after therapy, in real patients.
06 — What's next
From archive to engine.
Histonyx Network
A connected lab information system that grows the dataset lab by lab, with clear data rights built in.
Diagnostics with pharma
Co-developing tissue-based tests alongside new therapies.
Privacy by design
Data is released only in de-identified form under a signed data use agreement. Slide images are checked for labels and identifiers before release. Trial recruitment runs separately, through patients' own physicians and with consent — never by re-identifying licensed data.
Start here
Send us a protocol.
We'll send back the patients.
A feasibility count for one indication: cohort sizes, stain coverage, and treatment-history ranges.